Lenalidomide-Associated ITP.
Publication
, Journal Article
Herold, CI; Gasparetto, C; Arepally, GM
Published in: Case Rep Hematol
2011
Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia. The common toxicities of lenalidomide, including dose-limiting myelosuppression, are well described. However, the immunomodulatory properties of lenalidomide may give rise to unexpected autoimmune complications. Herein, we describe a case of immune thrombocytopenic purpura (ITP) associated with use of lenalidomide.
Duke Scholars
Published In
Case Rep Hematol
DOI
EISSN
2090-6579
Publication Date
2011
Volume
2011
Start / End Page
638020
Location
United States
Citation
APA
Chicago
ICMJE
MLA
NLM
Herold, C. I., Gasparetto, C., & Arepally, G. M. (2011). Lenalidomide-Associated ITP. Case Rep Hematol, 2011, 638020. https://doi.org/10.1155/2011/638020
Herold, Christina I., Cristina Gasparetto, and Gowthami M. Arepally. “Lenalidomide-Associated ITP.” Case Rep Hematol 2011 (2011): 638020. https://doi.org/10.1155/2011/638020.
Herold CI, Gasparetto C, Arepally GM. Lenalidomide-Associated ITP. Case Rep Hematol. 2011;2011:638020.
Herold, Christina I., et al. “Lenalidomide-Associated ITP.” Case Rep Hematol, vol. 2011, 2011, p. 638020. Pubmed, doi:10.1155/2011/638020.
Herold CI, Gasparetto C, Arepally GM. Lenalidomide-Associated ITP. Case Rep Hematol. 2011;2011:638020.
Published In
Case Rep Hematol
DOI
EISSN
2090-6579
Publication Date
2011
Volume
2011
Start / End Page
638020
Location
United States